|Day Low/High||42.95 / 44.05|
|52 Wk Low/High||29.95 / 65.64|
The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 836,945 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 6,219,273, an increase of 15.55% since 01/13/2017.
Pacira Pharmaceuticals, Clearside Biomedical and Organovo Holdings are among the premarket biotech movers on Wednesday.
EXPAREL® Provides Orthopaedic Patients Long-Lasting, Non-Opioid Postsurgical Pain Control at the Surgical Site
EXPAREL net product sales driven by soft tissue and orthopedic procedures
Typically, the best way to get sentiment to turn is to take the indexes down.
Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2017 expiration.
Collaboration will leverage genetic testing to identify patients predisposed to developing addiction following opioid exposure
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the January 2017 expiration.
Pacira grant will allow for the development and distribution of resources to educate patients and surgeons on opioid use in surgical care
3D Mobile Simulation Will Also Debut in Pacira Booth #907 at AAHKS 2016
Here are Thursday's top research calls, including an upgrade for Western Digital and downgrades for Quintiles and Royal Caribbean.
Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the December 16th expiration.
Company Appoints Thomas Sluby as Vice President, Sales and Matthew Lehmann as Vice President, Marketing
New research presented at AAOMS 2016 shows EXPAREL is safe and effective for pain relief following removal of wisdom teeth
Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a strong on high relative volume candidate